These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 32352653)

  • 41. HLA antigens, psoriasis and acute anterior uveitis in Bechterew's syndrome (ankylosing spondylitis).
    Møller P; Vinje O; Berg K
    Clin Genet; 1982 Mar; 21(3):215-21. PubMed ID: 6980067
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Long-term effects of interleukin-17A inhibition with secukinumab in active ankylosing spondylitis: 3-year efficacy and safety results from an extension of the Phase 3 MEASURE 1 trial.
    Baraliakos X; Kivitz AJ; Deodhar AA; Braun J; Wei JC; Delicha EM; Talloczy Z; Porter B;
    Clin Exp Rheumatol; 2018; 36(1):50-55. PubMed ID: 28516874
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cost-effectiveness analysis of secukinumab in ankylosing spondylitis from the Canadian perspective.
    Goeree R; Chiva-Razavi S; Gunda P; Jain M; Jugl SM
    J Med Econ; 2019 Jan; 22(1):45-52. PubMed ID: 30346844
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b/3 trials.
    Brown MA; Rudwaleit M; van Gaalen FA; Haroon N; Gensler LS; Fleurinck C; Marten A; Massow U; de Peyrecave N; Vaux T; White K; Deodhar A; van der Horst-Bruinsma I
    Ann Rheum Dis; 2024 Aug; ():. PubMed ID: 38977276
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy of Secukinumab for Moderate-to-Severe Head and Neck Psoriasis Over 52 Weeks: Pooled Analysis of Four Phase 3 Studies.
    Kircik L; Fowler J; Weiss J; Meng X; Guana A; Nyirady J
    Dermatol Ther (Heidelb); 2016 Dec; 6(4):627-638. PubMed ID: 27573260
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Secukinumab after anti-tumour necrosis factor-α therapy: a phase III study in active rheumatoid arthritis.
    Dokoupilová E; Aelion J; Takeuchi T; Malavolta N; Sfikakis PP; Wang Y; Rohrer S; Richards HB
    Scand J Rheumatol; 2018 Jul; 47(4):276-281. PubMed ID: 29458278
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Uveitis in spondyloarthritis including psoriatic arthritis, ankylosing spondylitis, and inflammatory bowel disease.
    Rosenbaum JT
    Clin Rheumatol; 2015 Jun; 34(6):999-1002. PubMed ID: 25953065
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Choroidal thickness changes determined by EDI-OCT on acute anterior uveitis in patients with HLA-B27-positive ankylosing spondylitis.
    Basarir B; Celik U; Altan C; Celik NB
    Int Ophthalmol; 2018 Feb; 38(1):307-312. PubMed ID: 28197814
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Secukinumab (AIN457) in the treatment of ankylosing spondylitis.
    Braun J; Baraliakos X; Kiltz U
    Expert Opin Biol Ther; 2016; 16(5):711-22. PubMed ID: 26982813
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study.
    McInnes IB; Mease PJ; Schett G; Kirkham B; Strand V; Williams N; Fox T; Pricop L; Jugl SM; Gandhi KK;
    Arthritis Res Ther; 2018 Jun; 20(1):113. PubMed ID: 29880010
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Secukinumab Improves Physical Function in Subjects With Plaque Psoriasis and Psoriatic Arthritis: Results from Two Randomized, Phase 3 Trials.
    Gottlieb AB; Langley RG; Philipp S; Sigurgeirsson B; Blauvelt A; Martin R; Papavassilis C; Mpofu S
    J Drugs Dermatol; 2015 Aug; 14(8):821-33. PubMed ID: 26267726
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Secukinumab induced Behçet's syndrome: a report of two cases.
    Dincses E; Yurttas B; Esatoglu SN; Melikoglu M; Hamuryudan V; Seyahi E
    Oxf Med Case Reports; 2019 May; 2019(5):omz041. PubMed ID: 31198577
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy.
    Letko E; Yeh S; Foster CS; Pleyer U; Brigell M; Grosskreutz CL;
    Ophthalmology; 2015 May; 122(5):939-48. PubMed ID: 25638011
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits low immunogenicity in psoriasis patients treated up to 5 years.
    Reich K; Blauvelt A; Armstrong A; Langley RG; de Vera A; Kolbinger F; Spindeldreher S; Ren M; Bruin G
    J Eur Acad Dermatol Venereol; 2019 Sep; 33(9):1733-1741. PubMed ID: 31009130
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Two-year incidence of psoriasis, uveitis and inflammatory bowel disease in patients with spondyloarthritis: A study in the AQUILES cohort.
    García-Vicuña R; Zarco P; González CM; Vanaclocha F; Marín-Jiménez I; Cea-Calvo L
    Reumatol Clin; 2016; 12(1):22-6. PubMed ID: 25683367
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy of Secukinumab on Moderate-to-severe Plaque Psoriasis Affecting Different Body Regions: a Pooled Analysis of Four Phase 3 Studies.
    Menter A; Cather JC; Jarratt M; Meng X; Guana A; Nyirady J
    Dermatol Ther (Heidelb); 2016 Dec; 6(4):639-647. PubMed ID: 27576559
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Long-Term Safety of Adalimumab in 29,967 Adult Patients From Global Clinical Trials Across Multiple Indications: An Updated Analysis.
    Burmester GR; Gordon KB; Rosenbaum JT; Arikan D; Lau WL; Li P; Faccin F; Panaccione R
    Adv Ther; 2020 Jan; 37(1):364-380. PubMed ID: 31748904
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Secukinumab provides rapid and persistent relief in pain and fatigue symptoms in patients with ankylosing spondylitis irrespective of baseline C-reactive protein levels or prior tumour necrosis factor inhibitor therapy: 2-year data from the MEASURE 2 study.
    Deodhar A; Conaghan PG; Kvien TK; Strand V; Sherif B; Porter B; Jugl SM; Gandhi KK;
    Clin Exp Rheumatol; 2019; 37(2):260-269. PubMed ID: 30148436
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Secukinumab: A Review in Psoriatic Arthritis.
    Shirley M; Scott LJ
    Drugs; 2016 Jul; 76(11):1135-45. PubMed ID: 27299434
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A familial study of the inheritance of HLA-B27-positive acute anterior uveitis.
    Derhaag PJ; Linssen A; Broekema N; de Waal LP; Feltkamp TE
    Am J Ophthalmol; 1988 Jun; 105(6):603-6. PubMed ID: 3259836
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.